James Marsh
Concepts (510)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 46 | 2008 | 471 | 2.230 |
Why?
| | Calcium Channels, L-Type | 17 | 2008 | 69 | 1.750 |
Why?
| | Myocardial Contraction | 35 | 2010 | 109 | 1.290 |
Why?
| | Calcium | 32 | 2017 | 396 | 0.920 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2017 | 211 | 0.870 |
Why?
| | Stroke | 3 | 2019 | 527 | 0.850 |
Why?
| | Calcium Channels | 11 | 2006 | 42 | 0.820 |
Why?
| | Genetic Therapy | 3 | 2009 | 127 | 0.800 |
Why?
| | Blood Platelets | 3 | 2017 | 239 | 0.780 |
Why?
| | Platelet Function Tests | 2 | 2013 | 21 | 0.780 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2013 | 34 | 0.750 |
Why?
| | Rats | 37 | 2010 | 3228 | 0.720 |
Why?
| | Ion Channels | 9 | 2009 | 74 | 0.700 |
Why?
| | Coronary Disease | 6 | 2004 | 145 | 0.650 |
Why?
| | Myocytes, Cardiac | 8 | 2010 | 146 | 0.650 |
Why?
| | Brain Ischemia | 2 | 2019 | 168 | 0.620 |
Why?
| | Heart | 16 | 2002 | 352 | 0.590 |
Why?
| | Fluorocarbons | 1 | 2019 | 59 | 0.590 |
Why?
| | Biomedical Research | 3 | 2018 | 260 | 0.580 |
Why?
| | Neuroprotective Agents | 1 | 2019 | 103 | 0.580 |
Why?
| | Cells, Cultured | 39 | 2008 | 1583 | 0.560 |
Why?
| | Research Personnel | 2 | 2018 | 71 | 0.560 |
Why?
| | Animals | 68 | 2012 | 13485 | 0.560 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2006 | 135 | 0.550 |
Why?
| | Receptors, Adrenergic, beta | 11 | 2000 | 44 | 0.550 |
Why?
| | Personnel Selection | 1 | 2017 | 25 | 0.540 |
Why?
| | Internal Medicine | 1 | 2017 | 21 | 0.540 |
Why?
| | Cardiovascular Diseases | 4 | 2020 | 493 | 0.520 |
Why?
| | Heart Ventricles | 20 | 2010 | 259 | 0.510 |
Why?
| | Leadership | 1 | 2017 | 105 | 0.510 |
Why?
| | Faculty, Medical | 1 | 2017 | 92 | 0.510 |
Why?
| | Isoproterenol | 14 | 2002 | 56 | 0.450 |
Why?
| | Physician's Role | 1 | 2014 | 50 | 0.440 |
Why?
| | Sodium-Calcium Exchanger | 6 | 2004 | 8 | 0.430 |
Why?
| | RNA, Messenger | 17 | 2005 | 1134 | 0.410 |
Why?
| | Education, Medical | 1 | 2014 | 112 | 0.400 |
Why?
| | Chest Pain | 1 | 2013 | 55 | 0.390 |
Why?
| | Rats, Sprague-Dawley | 20 | 2005 | 1558 | 0.390 |
Why?
| | Ticlopidine | 1 | 2013 | 71 | 0.390 |
Why?
| | Coronary Artery Disease | 3 | 2012 | 323 | 0.370 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 2012 | 168 | 0.360 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2010 | 148 | 0.340 |
Why?
| | Transcription, Genetic | 6 | 2002 | 375 | 0.330 |
Why?
| | Acute Coronary Syndrome | 1 | 2012 | 106 | 0.330 |
Why?
| | Excitation Contraction Coupling | 1 | 2010 | 3 | 0.330 |
Why?
| | Calcium Signaling | 1 | 2010 | 57 | 0.320 |
Why?
| | Calcium Channel Blockers | 7 | 1997 | 60 | 0.310 |
Why?
| | Cardiomegaly | 3 | 1998 | 55 | 0.310 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 465 | 0.300 |
Why?
| | Hypertension | 5 | 2020 | 560 | 0.300 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 521 | 0.300 |
Why?
| | Protein Subunits | 4 | 2008 | 79 | 0.290 |
Why?
| | Chick Embryo | 23 | 1993 | 79 | 0.280 |
Why?
| | Norepinephrine | 4 | 2002 | 106 | 0.280 |
Why?
| | Molecular Mimicry | 1 | 2008 | 35 | 0.280 |
Why?
| | Troponin I | 1 | 2008 | 19 | 0.270 |
Why?
| | Sarcoplasmic Reticulum | 4 | 2010 | 21 | 0.270 |
Why?
| | Humans | 33 | 2020 | 52441 | 0.260 |
Why?
| | Drug Design | 1 | 2008 | 122 | 0.260 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2008 | 62 | 0.260 |
Why?
| | Time Factors | 9 | 2019 | 2987 | 0.250 |
Why?
| | Male | 31 | 2019 | 26874 | 0.250 |
Why?
| | Muscle Proteins | 5 | 2007 | 343 | 0.230 |
Why?
| | RNA Splice Sites | 1 | 2005 | 10 | 0.230 |
Why?
| | Arteriosclerosis | 1 | 2004 | 49 | 0.220 |
Why?
| | Testosterone | 6 | 2005 | 145 | 0.220 |
Why?
| | Alternative Splicing | 1 | 2005 | 61 | 0.220 |
Why?
| | Stents | 3 | 2013 | 368 | 0.220 |
Why?
| | Receptors, Adrenergic | 2 | 2001 | 14 | 0.220 |
Why?
| | Mutation | 2 | 2008 | 1331 | 0.220 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 938 | 0.210 |
Why?
| | Ventricular Function | 7 | 2005 | 17 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 125 | 0.210 |
Why?
| | United States | 7 | 2018 | 5215 | 0.210 |
Why?
| | Adrenergic beta-Agonists | 6 | 2001 | 39 | 0.200 |
Why?
| | Receptors, Androgen | 3 | 2005 | 48 | 0.200 |
Why?
| | Gene Expression Regulation | 6 | 2006 | 1004 | 0.200 |
Why?
| | Muscle Cells | 1 | 2003 | 20 | 0.200 |
Why?
| | Apoptosis | 2 | 2005 | 1120 | 0.200 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2002 | 19 | 0.190 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2001 | 63 | 0.190 |
Why?
| | Glucose | 1 | 2005 | 356 | 0.190 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 46 | 0.190 |
Why?
| | Cell Membrane | 4 | 2017 | 238 | 0.190 |
Why?
| | Muscle Contraction | 1 | 2003 | 109 | 0.190 |
Why?
| | Risk Factors | 6 | 2020 | 3971 | 0.190 |
Why?
| | Vasoconstrictor Agents | 1 | 2002 | 81 | 0.180 |
Why?
| | Treatment Outcome | 4 | 2019 | 5508 | 0.180 |
Why?
| | Peptides | 1 | 2002 | 239 | 0.180 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 404 | 0.170 |
Why?
| | Female | 18 | 2019 | 28277 | 0.170 |
Why?
| | Estrogens, Non-Steroidal | 1 | 2000 | 16 | 0.170 |
Why?
| | 5' Untranslated Regions | 1 | 2000 | 30 | 0.160 |
Why?
| | Plants | 1 | 2000 | 28 | 0.160 |
Why?
| | Kinetics | 9 | 2010 | 613 | 0.160 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2001 | 21 | 0.160 |
Why?
| | Phenylephrine | 4 | 2001 | 36 | 0.160 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 39 | 0.150 |
Why?
| | Isoflavones | 1 | 2000 | 92 | 0.150 |
Why?
| | Sulfonamides | 1 | 2000 | 137 | 0.150 |
Why?
| | Orchiectomy | 3 | 2004 | 38 | 0.150 |
Why?
| | Sex Factors | 2 | 2013 | 735 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 73 | 0.150 |
Why?
| | Angiotensin II | 3 | 1999 | 156 | 0.150 |
Why?
| | Multivariate Analysis | 2 | 2013 | 601 | 0.150 |
Why?
| | Disability Evaluation | 1 | 2019 | 92 | 0.150 |
Why?
| | Nitric Oxide Donors | 1 | 1998 | 9 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2002 | 475 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 370 | 0.150 |
Why?
| | Recovery of Function | 1 | 2019 | 201 | 0.140 |
Why?
| | Genetic Vectors | 2 | 2009 | 128 | 0.140 |
Why?
| | Middle Aged | 10 | 2019 | 13133 | 0.140 |
Why?
| | Base Sequence | 4 | 2005 | 632 | 0.140 |
Why?
| | Logistic Models | 2 | 2013 | 930 | 0.140 |
Why?
| | Animals, Newborn | 7 | 2007 | 355 | 0.140 |
Why?
| | Risk Assessment | 2 | 2013 | 1349 | 0.140 |
Why?
| | Women | 1 | 2017 | 31 | 0.140 |
Why?
| | Double-Blind Method | 1 | 2019 | 726 | 0.130 |
Why?
| | Schools, Medical | 1 | 2017 | 68 | 0.130 |
Why?
| | Mitochondria, Heart | 4 | 2005 | 39 | 0.130 |
Why?
| | Platelet Activation | 1 | 2017 | 46 | 0.130 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 5 | 1993 | 9 | 0.130 |
Why?
| | Signal Transduction | 3 | 2017 | 1724 | 0.130 |
Why?
| | Blotting, Northern | 3 | 2002 | 107 | 0.130 |
Why?
| | Nitric Oxide | 1 | 1998 | 238 | 0.130 |
Why?
| | Epinephrine | 1 | 2017 | 92 | 0.130 |
Why?
| | Minority Groups | 1 | 2017 | 136 | 0.130 |
Why?
| | Endothelium, Vascular | 3 | 2004 | 263 | 0.120 |
Why?
| | Serotonin | 1 | 2017 | 149 | 0.120 |
Why?
| | Receptors, Cholinergic | 1 | 1996 | 15 | 0.120 |
Why?
| | Down-Regulation | 2 | 2008 | 348 | 0.120 |
Why?
| | Catecholamines | 3 | 1996 | 44 | 0.120 |
Why?
| | Algorithms | 3 | 2013 | 673 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 217 | 0.120 |
Why?
| | Cardiotonic Agents | 2 | 2010 | 70 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1996 | 146 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 1999 | 449 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2008 | 95 | 0.110 |
Why?
| | Thrombolytic Therapy | 2 | 2010 | 113 | 0.110 |
Why?
| | Ribonucleosides | 1 | 1994 | 2 | 0.110 |
Why?
| | Aminoimidazole Carboxamide | 1 | 1994 | 2 | 0.110 |
Why?
| | Physicians | 1 | 2018 | 237 | 0.110 |
Why?
| | Protein Isoforms | 3 | 2007 | 127 | 0.110 |
Why?
| | Age Factors | 2 | 2013 | 1120 | 0.110 |
Why?
| | Bradykinin | 3 | 1999 | 18 | 0.110 |
Why?
| | DNA, Complementary | 2 | 2008 | 129 | 0.110 |
Why?
| | Gene Expression | 5 | 2003 | 618 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1994 | 53 | 0.110 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2004 | 7 | 0.100 |
Why?
| | Cyclic AMP | 5 | 2000 | 90 | 0.100 |
Why?
| | Blood Pressure | 3 | 2006 | 525 | 0.100 |
Why?
| | Arkansas | 1 | 2019 | 2013 | 0.100 |
Why?
| | Smoking | 1 | 2017 | 514 | 0.100 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2013 | 17 | 0.100 |
Why?
| | Dihydropyridines | 3 | 1993 | 7 | 0.100 |
Why?
| | Educational Measurement | 1 | 2014 | 196 | 0.100 |
Why?
| | NAD | 2 | 2002 | 46 | 0.100 |
Why?
| | Drug Resistance | 1 | 2013 | 69 | 0.100 |
Why?
| | Therapy, Computer-Assisted | 1 | 2013 | 33 | 0.100 |
Why?
| | Calsequestrin | 3 | 2007 | 3 | 0.100 |
Why?
| | Cell Line | 2 | 2008 | 1020 | 0.100 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 36 | 0.100 |
Why?
| | Tachycardia, Ventricular | 1 | 2013 | 45 | 0.100 |
Why?
| | Beriberi | 1 | 2012 | 5 | 0.100 |
Why?
| | Ganglia, Sympathetic | 1 | 1992 | 3 | 0.090 |
Why?
| | Defibrillators, Implantable | 1 | 2013 | 63 | 0.090 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 1988 | 22 | 0.090 |
Why?
| | Binding Sites | 5 | 2002 | 379 | 0.090 |
Why?
| | Cell Communication | 1 | 1992 | 74 | 0.090 |
Why?
| | Lipoproteins, LDL | 3 | 2004 | 177 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2012 | 81 | 0.090 |
Why?
| | Protein Kinase C | 2 | 2002 | 72 | 0.090 |
Why?
| | Odds Ratio | 1 | 2013 | 563 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2012 | 73 | 0.090 |
Why?
| | Electrocardiography | 1 | 2013 | 273 | 0.090 |
Why?
| | Immunoblotting | 2 | 2002 | 118 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2002 | 778 | 0.090 |
Why?
| | Incidence | 2 | 2008 | 1096 | 0.080 |
Why?
| | International Normalized Ratio | 1 | 2010 | 29 | 0.080 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 50 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 271 | 0.080 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 42 | 0.080 |
Why?
| | Diabetic Angiopathies | 1 | 2010 | 24 | 0.080 |
Why?
| | Cardiomyopathies | 3 | 2002 | 117 | 0.080 |
Why?
| | Intracranial Hemorrhages | 1 | 2010 | 43 | 0.080 |
Why?
| | Foramen Ovale, Patent | 1 | 2010 | 31 | 0.080 |
Why?
| | Endarterectomy, Carotid | 1 | 2010 | 60 | 0.080 |
Why?
| | Adenoviridae | 3 | 2007 | 46 | 0.080 |
Why?
| | Action Potentials | 1 | 2010 | 128 | 0.080 |
Why?
| | Thrombectomy | 1 | 2010 | 74 | 0.080 |
Why?
| | Aged | 5 | 2013 | 10242 | 0.080 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2000 | 3 | 0.080 |
Why?
| | Warfarin | 1 | 2010 | 81 | 0.080 |
Why?
| | Gene Transfer Techniques | 1 | 2009 | 44 | 0.080 |
Why?
| | Gene Targeting | 1 | 2009 | 29 | 0.080 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2013 | 328 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 112 | 0.070 |
Why?
| | Prognosis | 2 | 2008 | 2100 | 0.070 |
Why?
| | Protein Engineering | 1 | 2008 | 18 | 0.070 |
Why?
| | Rats, Inbred WKY | 1 | 2008 | 27 | 0.070 |
Why?
| | Rats, Inbred SHR | 1 | 2008 | 37 | 0.070 |
Why?
| | Protein Modification, Translational | 1 | 2007 | 3 | 0.070 |
Why?
| | Nifedipine | 4 | 1990 | 25 | 0.070 |
Why?
| | Glasgow Coma Scale | 1 | 2008 | 42 | 0.070 |
Why?
| | Spectrometry, Fluorescence | 2 | 2002 | 46 | 0.070 |
Why?
| | Atrial Fibrillation | 1 | 2010 | 196 | 0.070 |
Why?
| | Heart Diseases | 1 | 2010 | 217 | 0.070 |
Why?
| | Acidosis | 1 | 1988 | 41 | 0.070 |
Why?
| | Cerebrovascular Disorders | 1 | 2008 | 46 | 0.070 |
Why?
| | Mesenteric Arteries | 1 | 2008 | 39 | 0.070 |
Why?
| | Medical Records | 1 | 2008 | 83 | 0.070 |
Why?
| | Thrombosis | 1 | 2010 | 250 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2008 | 85 | 0.070 |
Why?
| | Triiodothyronine | 1 | 1987 | 27 | 0.070 |
Why?
| | Homeostasis | 4 | 2002 | 206 | 0.070 |
Why?
| | Anticoagulants | 1 | 2010 | 276 | 0.070 |
Why?
| | Oxadiazoles | 1 | 1987 | 9 | 0.070 |
Why?
| | Cell Culture Techniques | 2 | 2005 | 97 | 0.070 |
Why?
| | Heart Rate | 3 | 2001 | 311 | 0.070 |
Why?
| | Cholesterol | 1 | 2008 | 159 | 0.070 |
Why?
| | Dogs | 3 | 2007 | 183 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 177 | 0.070 |
Why?
| | Prospective Studies | 1 | 2013 | 2433 | 0.070 |
Why?
| | Propranolol | 3 | 1994 | 76 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2017 | 107 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2008 | 102 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 137 | 0.060 |
Why?
| | Pyridones | 1 | 1987 | 35 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 570 | 0.060 |
Why?
| | Aorta | 2 | 2005 | 170 | 0.060 |
Why?
| | 1-Methyl-3-isobutylxanthine | 4 | 1998 | 8 | 0.060 |
Why?
| | Verapamil | 5 | 1994 | 19 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 1987 | 90 | 0.060 |
Why?
| | Adult | 9 | 2017 | 14205 | 0.060 |
Why?
| | Angina Pectoris | 1 | 1986 | 19 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 148 | 0.060 |
Why?
| | Arteriovenous Fistula | 1 | 1986 | 27 | 0.060 |
Why?
| | Carotid Stenosis | 1 | 2006 | 61 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2007 | 312 | 0.060 |
Why?
| | Aortic Aneurysm | 1 | 1986 | 28 | 0.060 |
Why?
| | Vena Cava, Inferior | 1 | 1986 | 61 | 0.060 |
Why?
| | Aortic Diseases | 1 | 1986 | 54 | 0.060 |
Why?
| | Hospital Mortality | 1 | 2008 | 451 | 0.060 |
Why?
| | Cytoskeleton | 1 | 1985 | 38 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 1985 | 47 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2005 | 11 | 0.060 |
Why?
| | Mannitol | 1 | 2005 | 14 | 0.060 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2005 | 20 | 0.060 |
Why?
| | Alprenolol | 1 | 1985 | 1 | 0.060 |
Why?
| | Restriction Mapping | 1 | 2005 | 33 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 130 | 0.060 |
Why?
| | Tumor Necrosis Factors | 1 | 2004 | 7 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2005 | 54 | 0.060 |
Why?
| | Casein Kinase II | 1 | 2004 | 9 | 0.060 |
Why?
| | Muscle, Smooth | 1 | 2004 | 63 | 0.060 |
Why?
| | DNA Primers | 1 | 2005 | 204 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2005 | 181 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2005 | 175 | 0.060 |
Why?
| | bcl-X Protein | 1 | 2005 | 53 | 0.060 |
Why?
| | Myosin Heavy Chains | 1 | 2004 | 25 | 0.050 |
Why?
| | Coronary Artery Bypass | 2 | 2010 | 135 | 0.050 |
Why?
| | Ligands | 1 | 2004 | 205 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 260 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2020 | 129 | 0.050 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 34 | 0.050 |
Why?
| | Calcium Radioisotopes | 3 | 1989 | 7 | 0.050 |
Why?
| | Pyridines | 1 | 1985 | 137 | 0.050 |
Why?
| | Temperature | 1 | 2004 | 166 | 0.050 |
Why?
| | Gonadal Steroid Hormones | 2 | 2003 | 41 | 0.050 |
Why?
| | Androgens | 1 | 2004 | 70 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 580 | 0.050 |
Why?
| | Angiography | 1 | 1983 | 111 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1028 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2003 | 47 | 0.050 |
Why?
| | Ion Channel Gating | 2 | 2006 | 37 | 0.050 |
Why?
| | DNA Footprinting | 1 | 2002 | 8 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2003 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2002 | 8 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2002 | 43 | 0.050 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 71 | 0.050 |
Why?
| | Pulmonary Embolism | 1 | 1983 | 81 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2003 | 142 | 0.050 |
Why?
| | Vasodilation | 1 | 2003 | 99 | 0.050 |
Why?
| | Cardiac Pacing, Artificial | 2 | 1994 | 33 | 0.050 |
Why?
| | Proteins | 1 | 2005 | 353 | 0.050 |
Why?
| | Macrophages | 1 | 2004 | 357 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 146 | 0.050 |
Why?
| | Receptors, Nicotinic | 2 | 1992 | 73 | 0.050 |
Why?
| | Lovastatin | 2 | 1993 | 9 | 0.050 |
Why?
| | Acute Disease | 1 | 2002 | 384 | 0.040 |
Why?
| | Blotting, Western | 1 | 2003 | 587 | 0.040 |
Why?
| | Systole | 2 | 1990 | 71 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 458 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 378 | 0.040 |
Why?
| | Electrophysiology | 3 | 1996 | 70 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2002 | 142 | 0.040 |
Why?
| | Chronotherapy | 1 | 2020 | 2 | 0.040 |
Why?
| | Phenylalanine | 2 | 1999 | 139 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2002 | 247 | 0.040 |
Why?
| | Hemorrhage | 1 | 2002 | 225 | 0.040 |
Why?
| | Isoquinolines | 1 | 2000 | 21 | 0.040 |
Why?
| | Biological Transport | 1 | 2001 | 153 | 0.040 |
Why?
| | Electrophoresis | 1 | 2000 | 16 | 0.040 |
Why?
| | Phytoestrogens | 1 | 2000 | 23 | 0.040 |
Why?
| | Inflammation | 1 | 2004 | 649 | 0.040 |
Why?
| | Up-Regulation | 3 | 2017 | 462 | 0.040 |
Why?
| | Genetic Complementation Test | 1 | 2000 | 43 | 0.040 |
Why?
| | RNA, Antisense | 1 | 2000 | 6 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 461 | 0.040 |
Why?
| | Luciferases | 1 | 2000 | 50 | 0.040 |
Why?
| | Lung | 1 | 1983 | 479 | 0.040 |
Why?
| | Plant Preparations | 1 | 2000 | 41 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2000 | 86 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 95 | 0.040 |
Why?
| | Stimulation, Chemical | 3 | 1990 | 30 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2000 | 189 | 0.040 |
Why?
| | Decision Trees | 1 | 1999 | 23 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 1999 | 8 | 0.040 |
Why?
| | Transfection | 1 | 2000 | 365 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 1979 | 94 | 0.040 |
Why?
| | Transcription Factors | 1 | 2002 | 570 | 0.040 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 2 | 1993 | 59 | 0.040 |
Why?
| | omega-N-Methylarginine | 1 | 1998 | 3 | 0.040 |
Why?
| | Iloprost | 1 | 1998 | 3 | 0.040 |
Why?
| | Molsidomine | 1 | 1998 | 5 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1998 | 18 | 0.040 |
Why?
| | Nitroprusside | 1 | 1998 | 10 | 0.040 |
Why?
| | Indomethacin | 1 | 1998 | 36 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 11 | 0.040 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1998 | 41 | 0.030 |
Why?
| | Research Support as Topic | 1 | 2018 | 44 | 0.030 |
Why?
| | Propanolamines | 2 | 1988 | 13 | 0.030 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.030 |
Why?
| | Transglutaminases | 1 | 2017 | 14 | 0.030 |
Why?
| | Patch-Clamp Techniques | 1 | 1997 | 120 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 68 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 76 | 0.030 |
Why?
| | Polysaccharides | 1 | 2017 | 58 | 0.030 |
Why?
| | Cell Division | 3 | 2003 | 288 | 0.030 |
Why?
| | Heart Failure | 2 | 1993 | 527 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 172 | 0.030 |
Why?
| | Cell Movement | 2 | 2003 | 271 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 1998 | 267 | 0.030 |
Why?
| | Enkephalins | 2 | 1986 | 6 | 0.030 |
Why?
| | Glycosylation | 2 | 2007 | 104 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 333 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 255 | 0.030 |
Why?
| | Pindolol | 2 | 1985 | 4 | 0.030 |
Why?
| | GTP-Binding Proteins | 2 | 1993 | 86 | 0.030 |
Why?
| | Extracellular Space | 2 | 1993 | 38 | 0.030 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1994 | 2 | 0.030 |
Why?
| | Curriculum | 1 | 2018 | 406 | 0.030 |
Why?
| | Theophylline | 1 | 1994 | 20 | 0.030 |
Why?
| | Osmolar Concentration | 2 | 1991 | 61 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2017 | 1202 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 1994 | 136 | 0.030 |
Why?
| | Caspases | 2 | 2005 | 101 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 1988 | 1365 | 0.030 |
Why?
| | Phosphorylation | 2 | 2005 | 536 | 0.030 |
Why?
| | Cell Separation | 3 | 2005 | 78 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1993 | 34 | 0.030 |
Why?
| | Receptors, Drug | 1 | 1993 | 4 | 0.020 |
Why?
| | Digoxin | 1 | 1993 | 21 | 0.020 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 45 | 0.020 |
Why?
| | Internship and Residency | 1 | 2018 | 438 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 1994 | 1483 | 0.020 |
Why?
| | Isradipine | 2 | 1993 | 4 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 56 | 0.020 |
Why?
| | Ouabain | 3 | 1993 | 28 | 0.020 |
Why?
| | Potassium | 3 | 1993 | 54 | 0.020 |
Why?
| | Cyanides | 1 | 1991 | 4 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 1991 | 4 | 0.020 |
Why?
| | Potassium Chloride | 1 | 1991 | 18 | 0.020 |
Why?
| | Electron Transport | 1 | 1991 | 24 | 0.020 |
Why?
| | Lactates | 1 | 1991 | 30 | 0.020 |
Why?
| | Cricetinae | 3 | 2002 | 189 | 0.020 |
Why?
| | Deoxyglucose | 1 | 1991 | 35 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1991 | 184 | 0.020 |
Why?
| | Aorta, Abdominal | 2 | 1994 | 39 | 0.020 |
Why?
| | Malnutrition | 1 | 2012 | 89 | 0.020 |
Why?
| | Fluoresceins | 1 | 1990 | 9 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 871 | 0.020 |
Why?
| | Benzofurans | 1 | 1990 | 19 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 1991 | 234 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1991 | 327 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 1990 | 23 | 0.020 |
Why?
| | Infant | 1 | 1998 | 3709 | 0.020 |
Why?
| | Phenethylamines | 1 | 1989 | 8 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 2010 | 107 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 73 | 0.020 |
Why?
| | Cardiac Catheterization | 2 | 1983 | 228 | 0.020 |
Why?
| | Tritium | 2 | 1993 | 44 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 1223 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 1989 | 8 | 0.020 |
Why?
| | Sodium Channels | 1 | 1989 | 13 | 0.020 |
Why?
| | Depression, Chemical | 1 | 1988 | 12 | 0.020 |
Why?
| | Bupivacaine | 1 | 1989 | 29 | 0.020 |
Why?
| | Aspirin | 1 | 2010 | 122 | 0.020 |
Why?
| | Lidocaine | 1 | 1989 | 48 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1991 | 315 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1993 | 320 | 0.020 |
Why?
| | Culture Media | 2 | 1993 | 96 | 0.020 |
Why?
| | Amiloride | 1 | 1988 | 8 | 0.020 |
Why?
| | Oxygen | 2 | 1982 | 332 | 0.020 |
Why?
| | Aerobiosis | 1 | 1988 | 13 | 0.020 |
Why?
| | Anaerobiosis | 1 | 1988 | 21 | 0.020 |
Why?
| | Free Radicals | 1 | 1988 | 27 | 0.020 |
Why?
| | Catalase | 1 | 1988 | 72 | 0.020 |
Why?
| | Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 1 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 8 | 0.020 |
Why?
| | Tunicamycin | 1 | 2007 | 10 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2007 | 22 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 1988 | 120 | 0.020 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 13 | 0.020 |
Why?
| | COS Cells | 1 | 2007 | 76 | 0.020 |
Why?
| | Cell Membrane Permeability | 2 | 1987 | 24 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1988 | 178 | 0.020 |
Why?
| | Sarcolemma | 1 | 1987 | 3 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 609 | 0.020 |
Why?
| | Radioligand Assay | 1 | 1987 | 46 | 0.020 |
Why?
| | Milrinone | 1 | 1987 | 7 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2007 | 141 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2007 | 101 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1987 | 92 | 0.020 |
Why?
| | Pulmonary Circulation | 2 | 1983 | 26 | 0.020 |
Why?
| | Phenotype | 2 | 2003 | 792 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 9 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 16 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2006 | 113 | 0.010 |
Why?
| | Cats | 1 | 2005 | 84 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 292 | 0.010 |
Why?
| | bcl-2-Associated X Protein | 1 | 2005 | 58 | 0.010 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 21 | 0.010 |
Why?
| | Protein Conformation | 1 | 2006 | 178 | 0.010 |
Why?
| | Heart Neoplasms | 1 | 1985 | 30 | 0.010 |
Why?
| | Testosterone Propionate | 1 | 2005 | 2 | 0.010 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1985 | 1 | 0.010 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2004 | 16 | 0.010 |
Why?
| | Phosphates | 1 | 2004 | 51 | 0.010 |
Why?
| | Carcinoma | 1 | 1985 | 135 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1985 | 111 | 0.010 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1983 | 4 | 0.010 |
Why?
| | Nitrendipine | 1 | 1983 | 1 | 0.010 |
Why?
| | Echocardiography | 2 | 1993 | 409 | 0.010 |
Why?
| | Diltiazem | 1 | 1983 | 10 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 101 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1983 | 101 | 0.010 |
Why?
| | Pressure | 1 | 2003 | 100 | 0.010 |
Why?
| | Ion Exchange | 1 | 2002 | 1 | 0.010 |
Why?
| | Risk | 1 | 1983 | 315 | 0.010 |
Why?
| | Organ Size | 1 | 2002 | 226 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2004 | 210 | 0.010 |
Why?
| | Hemodynamics | 1 | 1983 | 235 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 269 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 816 | 0.010 |
Why?
| | Heart Atria | 2 | 1993 | 62 | 0.010 |
Why?
| | Dihydroalprenolol | 1 | 1980 | 3 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2013 | 6694 | 0.010 |
Why?
| | Chronic Disease | 1 | 2003 | 579 | 0.010 |
Why?
| | Sodium | 3 | 1987 | 92 | 0.010 |
Why?
| | Pulse | 1 | 1979 | 12 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 735 | 0.010 |
Why?
| | Oximetry | 1 | 1980 | 63 | 0.010 |
Why?
| | Carotid Arteries | 1 | 1979 | 77 | 0.010 |
Why?
| | Flavonoids | 1 | 1999 | 55 | 0.010 |
Why?
| | Sirolimus | 1 | 1999 | 72 | 0.010 |
Why?
| | Endothelium | 1 | 1998 | 38 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1983 | 1065 | 0.010 |
Why?
| | Naloxone | 2 | 1986 | 85 | 0.010 |
Why?
| | Prazosin | 1 | 1994 | 11 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1994 | 21 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1994 | 46 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 89 | 0.010 |
Why?
| | Turkeys | 1 | 1993 | 9 | 0.010 |
Why?
| | Computers | 1 | 1994 | 48 | 0.010 |
Why?
| | Virulence Factors, Bordetella | 1 | 1993 | 8 | 0.010 |
Why?
| | Pertussis Toxin | 1 | 1993 | 11 | 0.010 |
Why?
| | Neoplasms | 1 | 1983 | 1314 | 0.010 |
Why?
| | Cattle | 1 | 1993 | 197 | 0.010 |
Why?
| | Fetal Blood | 1 | 1993 | 78 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1992 | 13 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1993 | 558 | 0.010 |
Why?
| | Fibroblasts | 1 | 1994 | 357 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1993 | 174 | 0.010 |
Why?
| | Stroke Volume | 1 | 1993 | 148 | 0.010 |
Why?
| | Cell Survival | 1 | 1993 | 598 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1992 | 576 | 0.010 |
Why?
| | Mesocricetus | 1 | 1990 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 1990 | 2 | 0.010 |
Why?
| | Lanthanum | 1 | 1990 | 4 | 0.010 |
Why?
| | Diastole | 1 | 1990 | 68 | 0.010 |
Why?
| | Fluorescence | 1 | 1990 | 31 | 0.010 |
Why?
| | Calibration | 1 | 1990 | 56 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1990 | 91 | 0.010 |
Why?
| | Reference Values | 1 | 1990 | 316 | 0.010 |
Why?
| | Adenosine Diphosphate Ribose | 1 | 1989 | 7 | 0.000 |
Why?
| | Cholera Toxin | 1 | 1989 | 15 | 0.000 |
Why?
| | Atrial Function | 1 | 1989 | 7 | 0.000 |
Why?
| | Oxidative Phosphorylation | 1 | 1987 | 46 | 0.000 |
Why?
| | Glycolysis | 1 | 1987 | 70 | 0.000 |
Why?
| | Enkephalin, Methionine | 1 | 1986 | 2 | 0.000 |
Why?
| | Oxygen Consumption | 1 | 1987 | 193 | 0.000 |
Why?
| | Pulmonary Valve Stenosis | 1 | 1985 | 14 | 0.000 |
Why?
| | Receptors, Opioid | 1 | 1985 | 17 | 0.000 |
Why?
| | Aging | 1 | 1990 | 722 | 0.000 |
Why?
| | Adolescent | 1 | 1992 | 6713 | 0.000 |
Why?
| | Coronary Circulation | 1 | 1980 | 57 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1980 | 109 | 0.000 |
Why?
| | Hemoglobins | 1 | 1980 | 114 | 0.000 |
Why?
| | Brain | 1 | 1985 | 1337 | 0.000 |
Why?
|
|
Marsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|